Dr. Robin Y. Dulman
Claim this profileInova Fairfax Hospital
About Robin Y. Dulman
Education:
- Obtained MD from the University of Virginia School of Medicine in 2009.
- Completed Residency in Internal Medicine at the University of California, San Francisco (2009-2012).
- Undertook Fellowship in Pulmonary and Critical Care Medicine at the University of California, San Francisco (2012-2015).
Experience:
- Currently affiliated with Inova Fairfax Hospital as an Assistant Professor of Medicine.
- Specializes in Pulmonary and Critical Care Medicine.
Area of expertise
Burkitt Lymphoma
Robin Y. Dulman has run 6 trials for Burkitt Lymphoma. Some of their research focus areas include:
Rhabdomyosarcoma
Robin Y. Dulman has run 6 trials for Rhabdomyosarcoma. Some of their research focus areas include:
Affiliated Hospitals
Inova Fairfax Hospital
Clinical Trials Robin Y. Dulman is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting
2 awards
Phase 3
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting
2 awards
Phase 3
More about Robin Y. Dulman
Clinical Trial Related
6 years of experience running clinical trials · Led 27 trials as a Principal Investigator · 11 Active Clinical Trials
Treatments Robin Y. Dulman has experience with
- Cyclophosphamide
- Etoposide
- Vincristine Sulfate
- Doxorubicin Hydrochloride
- Radiation Therapy
- Mercaptopurine
Breakdown of trials Robin Y. Dulman has run
Burkitt Lymphoma
Rhabdomyosarcoma
Cancer
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Robin Y. Dulman specialize in?
Robin Y. Dulman focuses on Burkitt Lymphoma and Rhabdomyosarcoma. In particular, much of their work with Burkitt Lymphoma has involved Philadelphia chromosome positive patients, or patients who are BCR-ABL1 fusion positive.
Is Robin Y. Dulman currently recruiting for clinical trials?
Yes, Robin Y. Dulman is currently recruiting for 11 clinical trials in Falls Church Virginia. If you're interested in participating, you should apply.
Are there any treatments that Robin Y. Dulman has studied deeply?
Yes, Robin Y. Dulman has studied treatments such as Cyclophosphamide, Etoposide, Vincristine Sulfate.
What is the best way to schedule an appointment with Robin Y. Dulman?
Apply for one of the trials that Robin Y. Dulman is conducting.
What is the office address of Robin Y. Dulman?
The office of Robin Y. Dulman is located at: Inova Fairfax Hospital, Falls Church, Virginia 22042 United States. This is the address for their practice at the Inova Fairfax Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.